Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

P&G Announces Fiscal Year 2026 Second Quarter Results

View original at finance.yahoo.com
P&G Announces Fiscal Year 2026 Second Quarter Results Net Sales +1%; Organic Sales 0% Diluted EPS $1.78, -5%; Core EPS $1.88, 0% UPDATES GAAP EPS FOR RESTRUCTURING OUTLOOK MAINTAINS FISCAL YEAR SALES, CORE EPS GROWTH AND CASH RETURN GUIDANCE CINCINNATI, January 22, 2026--(BUSINESS WIRE)--The Procter & Gamble Company (N…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FY2026 organic sales growth guidance maintained at 0% to +4%

    80% confidence

  • Commodity costs expected to be neutral for FY2026 (updated from prior forecast)

    80% confidence

  • FY2026 core EPS growth guidance maintained at 0% to +4% (range $6.83 to $7.09)

    80% confidence

  • FY2026 diluted EPS growth revised down to +1% to +6% (from +3% to +9%) due to restructuring charges

    80% confidence

  • Tariff costs expected to create $400M after-tax headwind for FY2026

    80% confidence

  • P&G's strategy is to reinvent P&G and create the CPG company of the future, delivering long-term balanced top- and bottom-line growth

    80% confidence

  • P&G's Q2 results keep the company on track to deliver within fiscal year guidance ranges for organic sales growth, core EPS growth and adjusted free cash flow productivity in a challenging consumer and geopolitical environment

    80% confidence

  • FX expected to provide $200M after-tax tailwind for FY2026

    80% confidence

  • P&G has confidence in plans to deliver stronger results in the second half of fiscal year 2026

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
P&G Announces Fiscal Year 2026 Second Quarter Results — Source | Via News | ViaNews Market